Effects of Febuxostat for Lowering Uric Acid in NAFLD Patients With Gout
Status:
Not yet recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Nonalcoholic fatty liver disease (NAFLD) is the most common and harmful chronic liver
disease. NAFLD accounts for 49.3% of the total number of chronic liver disease patients in
China. It is important to effectively prevent and control NAFLD and its related diseases.
Previous studies show the level of serum uric acid is significantly elevated in patients with
NAFLD. Xanthine oxidase is a key enzyme in uric acid metabolism. It is a new therapeutic
target for NAFLD.
This study is aimed to further confirm that hyperuricemia is a new risk factor for NAFLD
through a large sample prospective study. Furthermore, this study explore whether Xanthine
oxidase (XO), a key enzyme in uric acid metabolism, plays an important role in regulating
NAFLD.